SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: David Cathcart who wrote (887)4/1/1998 4:49:00 PM
From: Biomaven  Respond to of 1826
 
<<One million people! >>

On the other hand, their just-released 10-K gives the estimated target population for Salagen for Sjogren's as 50,000. This seems overly cautious to me, but then maybe it was their l*wyer speaking. (Nobody ever got sued for being too cautious in a Prospectus or 10-K).

Peter



To: David Cathcart who wrote (887)4/2/1998 2:42:00 PM
From: gy  Read Replies (1) | Respond to of 1826
 
Don't understand why still some people are willing to sell the stocks around $8 when the stock showed great potency up to $12, or even $20 not too far.



To: David Cathcart who wrote (887)4/3/1998 1:55:00 PM
From: gy  Read Replies (1) | Respond to of 1826
 
One million people? If 30% of this market and $500 per patient per year, the revenues will be 150 millions. Let's say only 50% profit so that will be 75 millions. MGI now has about 15 million shares. The earning will be $5/share. What price of the stock will be with this earning? Remember, I did not count phase II development of MGI 114 and the European deal for MGI yet. May I be wrong somewhere?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News